Abstract
Breast epithelial cells produce both mitogens and growth inhibitors which are involved in the control of mammary gland development through autocrine and paracrine pathways. While the mechanisms of action of several growth factors have been well established and related strategies proposed for breast cancer therapy, little is known concerning growth inhibitors. In this review, we present an overview of current information about major autocrine and paracrine growth inhibitors of breast epithelial cells, and we discuss their potential functions in the control of breast cancer development.
Similar content being viewed by others
References
Böehmer FD, Kraft R, Otto A, Wernstedt C, Hellmann U, Kurtz A, Mueller T, Rohde K, Etzold G, Lehmann W, Langen P, Heldin CH, Grosse R: Identification of a polypeptide growth inhibitor from bovine mammary gland. J Biol Chem 262: 15137–15143, 1987
Lehmann W, Widmaire R, Langen P: Response of different epithelial cell lines to a mammary derived growth inhibitor (MDGI): Biomed Biochim Acta 48: 143–151, 1989
Spener F, Unterberg C, Borchers T, Grosse R: Characteristics of fatty acid-binding proteins and their relation to mammaryderived growth inhibitor. Mol Cell Biochem 98: 57–68, 1990
Specht B, Bartetzko N, Hohoff C, Kuhl H, Franke R, Börchers T, Spener F: Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein. J Biol Chem 271: 19943–19949, 1996
Börchers T, Hohoff C, Buhlmann C, Spener F: Heart-type fatty acid binding protein-involvement in growth inhibition and differentiation. Prostagalndins Leukot Essent Fatty Acids 57: 77–84, 1997
Yang Y, Spitzer E, Kenney N, Zschiesche W, Li M, Kromminga A, Muller T, Spener F, Lezius A, Veerkamp J, Smith G, Salomon D, Grosse R: Members of the fatty acid binding protein family are differentiation factors for the mammary gland. J Cell Biol 124: 1097–1109, 1994
Huynh H, Larsson C, Narod S, Pollak M: Tumour supressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 55: 2225–2231, 1995
Huynh H, Alpert L, Pollak M: Silencing of mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 56: 4865–4870, 1996
Massague J: TGF-beta signal transduction. Annu Rev Biochem 67: 753–791, 1998
Silberstein GB, Flanders KC, Roberts AB, Daniel CW: Regulation of mammary morphogenesis: Evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev Biol 152: 354–362, 1992
Pierce DJ, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BL, Moses HL: Inhibition of mammary duct development but not alveolar out-growth during pregnancy in transgenic mouse expressing active TGFb1. Genes Dev 7: 2308–2317, 1993
Strange R, Li F, Saurer S, Burkhardt A, Friis RR: Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115: 49–58, 1992
Valverius EM, Walker-Jones D, Bates SE, StampferMR, Clark R, Mc Cormick F, Dickson RB, Lippman ME: Production of and responsiveness to transforming growth factor-b in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 49: 6269–6274, 1989
Arteaga CL, Randon AK, Von Hoff DD, Osborne CK: Transforming growth factor-b: potencial autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898–3904, 1988
Zugmaler G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB: Transforming growth factor type b1 and b2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141: 353–361, 1989
Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGFb type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775–785, 1992
Kalkhoven E, Roelen BAJ, De Winter JP, Mummery CL, Van Den Eijnden-van Raaij AJM, Van Der Saag PT, Van Der Burg B: Resistance to transforming growth factor b and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6: 1151–1161, 1995
Sun L, Chen C: Expression of transforming growth factor b type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 272: 25367–25372, 1997
Chen C, Wang XF, Sun L: Expression of transforming growth factor-b (TGFb) type III receptor restores autocrine TGFb1 activity in human breast cancer MCF-7 cells. J Biol Chem 272: 12862–12867, 1997
De Winter JP, Roelen B, Ten Dijke P, Van Der burg B, Van Den Eijnden-Van Raaij A: DPC4 (SMAD4) mediates transforming growth factor-b1 (TGF-b1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14: 1891–1899, 1997
Gorsch SM, Memoli VA, Stukel TA, Gold L, Arrick BA: Immunohistochemical staining for transforming growth factor-b1 associates with disease progression in human breast cancer. Cancer Res 52: 6949–6952, 1992
Chua CC, Geiman DE, Keller GH, Ladda RL: Induction of collagenase secretion in human fibroblast cultures by growth promoting factors. J Biol Chem 260: 5213–5216, 1985
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699–704, 1990
Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90: 1843–1847, 1993
Welch DR, Fabra A, Nakajima M: Transforming growth factor b stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678–7682, 1990
Dong-Le Bourhis X, Lambrecht V, Boilly B: Transforming growth factor-beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells. Br J Cancer 77: 396–403, 1998
Larrick JW, Wright SC: Cytotoxic mechanism of tumor necrosis factor-a. FASEB J 4: 3215–3223, 1990
Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, LesslauerW, Loetscher H: Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87: 3127–3131, 1990
Varela LM, Ip MM: Tumor necrosis factor-a: A multifunctional regulator of mammary gland development. Endocrinology 137: 4915–4924, 1996
Dollbaum C, Creasey AA, Dairkee SH, Hiller AJ, Rudolph AR, Lin L, Vitt C, Smith HS: Specificity of tumor necrosis factor toxity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin. Proc Natl Acad Sci USA 85: 4740–4744, 1988
Jeoung D, Tang B, Sonenberg M: Effects of tumor necrosis factor-a on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J Biol Chem 270: 18367–18373, 1995
Liston P, Young SS, Mackenzie AE, Korneluk RG: Life and death decisions: the role of the IAPs in modulating programmed cell death. Apoptosis 2: 423–441, 1997
Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A: Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer 55: 926–930, 1993
Green AR, Green VR, White MC, Speirs V: Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72: 937–941, 1997
Serve H, Oelmann E, Herweg A, Oberberg D, Serve S, Reufi B, Mucke C, Minty A, Thiel E, Berdel WE: Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res 56: 3583–3588, 1996
Gooch JL, Lee AV, Yee D: Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58: 4199–4205, 1998
Chiu JJ, Kgagias MK, Cowan KH: Interleukin-6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 2: 215–221, 1996
Faggioli L, Costanzo C, Merola M, Bianchini E, Furia A, Carsana A, Palmieri M: Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. Eur J Biochem 239: 624–631, 1996
Haverty AA, Harmey JH, Redmond HP, Bouchier-Hayes DJ: Interleukin-6 upregulates GP96 expression in breast cancer. J Surg Res 69: 145–149, 1997
Figueroa JA, Yec D: The insulin-like growth factor binding proteins (IGFB Ps) in human breast cancer. Breast Cancer Res Treat 22: 381–390, 1992
Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, Papas T, Seth A: Down-regulation of TlAl2/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 16: 2459–2467, 1998
Baxter RC, Martin JL: Binding proteins for insulin-like growth factors: Structure, regulation, and function. Prog Growth Factor Res 1: 49–56, 1989
Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells. Biochem Biophys Res Commun 237: 690–693, 1997
Mohseni-Zadeh S, Binoux M: Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology 138: 5645–5648, 1997
Oh Y, Muller HL, Lamson G, Rosenfeld RG: Insulinlike growth factor (IGF)-independent action of IOF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem 268: 14964–14971, 1993
Oh Y, Muller HL, Pham HM, Rosenfeld RG: Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268: 26045–26048, 1993
Lalou C, Lassarre C, Binoux M: A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-1 and insulin. Endocrinology137: 3206–3212, 1996
Oh Y, Nagalla SN, Yamanaka Y, Kim H, Wilson L, Rosenfeld RG: Identification and characterization of insulin-like growth factor binding protein (IGFBP)-7: Recombinant human mac25 protein specially binds IGF-I and IGF-II. J Biol Chem 271: 30322–30325, 1996
Wilson EM, Oh Y, Rosenfeld RO: Generation and characterization of an IGFBP-7 antibody: identification of 31-kDa IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab 82: 1301–1303, 1997
Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and oestrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157: 229–236, 1993
Yee D, Jackson JG, Kozelsky TW, Figueroa JA: Insulin-like growth factor binding protein 1 expression inhibits insulinlike growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ 5: 73–77, 1994
Van Den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D: Polyethylene glycol conjugated insulinlike growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mouse. Eur J Cancer 33: 1108–1113, 1997
Toner E, Barber MC, Travers MT, Logan A, Flint DJ: Hormonal control of insulin-like growth factor-binding protein 5 production in the involuting mammary gland of the rat. Endocrinology 138: 5101–5107, 1997
Kjellen L and Lindahi U: Proteogltcans: structure and interactions. Annu Rev Biochem 60: 443–475, 1991
Rudland PS, Barraclough R, Fernig DG, Smith JA: Mammary stem cells in normal development and cancer. In: Potton C (ed) Stem Cells and Cancer. Churchill Livingstone, London, 1996, pp 147–232
Iozzo RV: Proteoglycans and neoplasia. Cancer Metast Res 7: 39–50, 1988
Delehedde M, Deudon E, Boilly B, Hondermarck H: Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity. Exp Cell Res 229: 398–406, 1996
Zhou FY, Owens RT, Hermoenen J, Hook M: Is the sensitivity of cells for FGF-1 and FGF-2 regulated by cell surface heparan sulfate proteoglycans? Eur Cell Biol 73: 166–174, 1996
Lambrecht V, Le Bourhis X, Toillon RA, Boilly B, Hondermarck H: Alterations in both heparan sulfate proteoglycans and mitogenic activity of fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal and breast cancer epithelial cells. Exp Cell Res 245: 239–244, 1998
Rahmoune H, Rudland PS, Gallagher JT, Fernig DG: Hepatocyte growth factor/scatter factor has distinct classes of binding site in heparan sulfate from mammary cells. Biochemistry 37: 6003–6008, 1998
Ervin PR, Kaminsky JMS, Cody RL, Wicha MS: Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science 244: 1585–1587, 1989
Masson PL, Heremans JF, Schonne E: Lactoferrin an iron binding protein in neutrophilic leukocytes. J Exp Med 130: 643–658, 1969
Damiens E, Mazurier J, El Yazidi I, Masson M, Duthille I, Spik G, Boilly-Marer Y: Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumor cells. Biochim Biophys Acta 1402: 277–287, 1998
Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, Boilly-Marer Y: Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 74: 486–498, 1999
Lai LC, Kadory S, Siraj AK, Lennard TW: Oncostatin M, interleukin 2, interleukin 6 and interleukin 8 in breast cyst fluid. Int J Cancer 59: 369–372, 1994
Liu J, Spence MJ, Wallace PM, Forcier K, Hellstrom I, Vestal RE: Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ 8: 667–676, 1997
Liu J, Hadjokas N, Mosley B, Estrov Z, SpenceMJ, Vestal RE: Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10: 295–302, 1998
Huynh H, Pollak M: Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. Clin Cancer Res 3: 2151–2156, 1997
Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that TGFb is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987
Pratt SE, Pollak MN: Insulin-like growth factor binding protein 3 (IGFBP-3) inhibits estrogen stimulated breast cancer cell proliferation. Biochem Biophy Res Commun 198: 292–297, 1994
Huynh H, Yang X, Pollak M: Estradiol and anti-estrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loup in human breast cancer cells. J Biol Chem 271: 1016–1021, 1996
Gucev ZS, Kelley KM, Rosenfeld RG, Oh Y: Insulin-like growth factor binding protein-3 (IGFBP-3) mediates retinoicacid (RA)-and transforming growth factor-b2 (TGF-b2)-induced growth inhibition in human breast cancer cells. Cancer Res 56: 1545–1550, 1996
Swisshelm K, Ryan K, Tsuchiya K, Sager R: Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA 92: 4472–4476, 1995
Kurtz A, Vogel F, Funa K, Heldin CH, Grosse R: Developmental regulation of mammary-derived growth inhibitor expression in bovine mammary tissue. J Cell Biol 110: 1779–1789, 1990
Wallach D, Kovalenko AV, Varfolomeev EE, Boldin MP: Death-inducing funtions of ligands of the tumor necrosis factor familly: a Sanhedrin verdict. Curr Opinion Immunol 10: 279–288, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bourhis, X.L., Toillon, RA., Boilly, B. et al. Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res Treat 60, 251–258 (2000). https://doi.org/10.1023/A:1006461621905
Issue Date:
DOI: https://doi.org/10.1023/A:1006461621905